Epithelial ovarian cancer

Current Treatment Options in Oncology

Volumn 3, Issue 2, 2002, Pages 131-141

  Hensley, Martee L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Carboplatin; Clin Oncol; Epithelial Ovarian Cancer; Ovarian Cancer; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DEOXYCYTIDINE; DOCETAXEL; DOXORUBICIN; DRUG DERIVATIVE; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE; TAXOID; TOPOTECAN; VINBLASTINE;

FEMALE; HUMAN; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY; PRACTICE GUIDELINE; REVIEW; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; PRACTICE GUIDELINES; TAMOXIFEN; TAXOIDS; TOPOTECAN; VINBLASTINE;

EID: 0036545870     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-002-0059-3     Document Type: Article

References (57)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999, 49:8–31. DOI: 10.3322/canjclin.49.1.8
2. Young RC, Walton LA, Ellenberg SS, et al.: Adjuvant therapy in stage I and II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990, 322:1021–1027. DOI: 10.1056/NEJM199004123221501
3. Hoskins WJ, McGuire WP, Brady MF, et al.: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994, 170:974–979.
4. Bonnefoi H, A'Hern RP, Fisher C, et al.: Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999, 17:767–775.
5. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1–6. DOI: 10.1056/NEJM199601043340101
6. Ford D, Easton DF, Bishop DT, et al.: Risk of cancer in BRCA1-mutation carriers. Lancet 1994, 343:692–695. DOI: 10.1016/S0140-6736(94)91578-4
7. Burke W, Daly M, Garber J, et al.: Recommendations for follow-up and care of individuals with inherited predisposition to cancer, II: BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997, 277:997–1003. DOI: 10.1001/jama.277.12.997
8. Ozols RF, Morgan RJ, Copeland L, et al.: Update of the NCCN ovarian cancer practice guidelines. Oncology 1997, 11:95–105.
9. McGowan L, Lesher LP, Norris HJ, Barnett M: Mis-staging of ovarian cancer. Obstet Gynecol 1985, 65:568–572.
10. van der Burg MEL, van Lent M, Buyse M, et al.: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995, 332:629–634. DOI: 10.1056/NEJM199503093321002
11. Barakat RR, Almadrones L, Venkatraman ES, et al.: A Phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage IIIV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 1998, 69:17–22. DOI: 10.1006/gyno.1998.4973
12. Young RC, Walton LA, Ellenberg SS, et al.: Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990, 322:1021–1027. DOI: 10.1056/NEJM199004123221501
13. Pecorelli S, Bolis G, Colombo N, et al.: Adjuvant therapy in early ovarian cancer. Proc Soc Gynecol Oncol 1994, A14.
14. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1–6. DOI: 10.1056/NEJM199601043340101
15. Piccart MJ, Bertelsen K, James K, et al.: Randomized intergroup trial of cisplatin-paclitaxel v. cisplatincyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000, 92:699–708. DOI: 10.1093/jnci/92.9.699
16. Neijt JP, Engelholm SA, Tuxen MK, et al.: Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000, 18:3084–3092.
17. Ozols RF, Bundy BN, Fowler J, et al.: Randomized Phase III study of cisplatin(CIS)/paclitaxel(PAC) versus carboplatin/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol 1999, 18:356a.
18. duBois A, Lueck HJ, Meier W, et al.: Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: update of an Arbeitgemeinschaft Gynaekologische Onkologie (AGO) study group trial. Proc Am Soc Clin Oncol 1999, 18:356a.
19. duBois A, Neijt JP, Thigpen JT: First-line chemotherapy the carboplatin plus paclitaxel in advanced ovarian cancer—a new standard of care? Ann Oncol 1999, 10:35–41. DOI: 10.1023/A:1008355317514
20. Ozols RF: Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol 2000, 27:3–7.
21. Weiss RB, Donehower RC, Wiernik PH, et al.: Hypersensitivity reactions from Taxol. J Clin Oncol 1990, 8:1263–1268.
22. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al.: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer. High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994, 12:2654–2666.
23. Markman M, Kennedy A, Webster K, et al.: Paclitaxelassociated hypersensitivity reactions: experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000, 18:102–105.
24. Peereboom DM, Donehower RC, Eisenhauer EA, et al.: Successful re-treatment with Taxol after major hypersensitivity reactions. J Clin Oncol 1993, 11:885–890.
25. Egorin MJ, vanEcho DA, Tipping SJ, et al.: Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclburanedicarboxylato)-platinum in patients with impaired renal function. Cancer Res 1984, 44:5432–5438.
26. Calvert AH, Newell DR, Gumbrell LA, et al.: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748–1756.
27. Markman M, Kennedy A, Webster K, et al.: Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999, 17:1141–1145.
28. Kintzel PE, Dorr RO: Anticancer drug renal toxicity and elimination. Dosing guidelines for altered renal function. Cancer Treat Rev 1995, 21:33–64. DOI: 10.1016/0305-7372(95)90010-1
29. Marty M, Pouillart P, Scholl S, et al.: Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in control of cisplatin-induced emesis. N Engl J Med 1990, 322:846–848. DOI: 10.1056/NEJM199003223221205
30. Morrow GR, Hickok JT, Rosenthal SN: Progress I reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 1995, 76:343–357. DOI: 10.1002/1097-0142(19950801)76:3<343::AID-CNCR2820760302>3.0.CO;2-V
31. Markman M, Rothman R, Hakes T, et al.: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991, 9:389–393.
32. Rose PG, Fusco N, Fluellen L, Rodriguez M: Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum ovarian or peritoneal carcinoma. J Clin Oncol 1998, 16:1494–1497.
33. Thigpen JT, Blessing JA, Ball H, et al.: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994, 12:1748–1753.
34. Zannotti KM, Belinson JL, Kennedy AW, et al.: Treatment of relapsed carcinoma of the ovary with singleagent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol 2000, 79:211–215. DOI: 10.1006/gyno.2000.5958
35. Abu-Rustum NR, Aghajanian C, Barakat R, et al.: Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 1997, 24:s62-s67.
36. McGuire WP, Blessing JA, Bookman MA, et al.: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000, 18:1062–1067.
37. Rose PG, Blessing JA, Mayer AR, et al.: Prolonged oral etoposide as second-line therapy for platinumresistant and platinum-sensitive ovarian carcinoma. A Gynecologic Oncology Group study. J Clin Oncol 1998, 16:405–410.
38. Creemers GJ, Bolis G, Gore M, et al.: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II trial. J Clin Oncol 1996, 14:3056–3061.
39. Kudelka AP, Tresukosol D, Edwards CL, et al.: Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996, 14:1552–1557.
40. ten Bokkel Huinink WW, Gore M, Carmichael J, et al.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997, 15:2183–2193.
41. Bookman MA, Malmstrom H, Bolis G, et al.: Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy containing cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998, 16:3345–3352.
42. Muggia FM, Hainsworth JD, Jeffers S, et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997, 15:987–993.
43. Gordon AN, Granai CO, Rose PG, et al.: Phase II study of liposomal doxorubicin in platinum- and paclitaxelrefractory epithelial ovarian cancer. J Clin Oncol 2000, 18:3093–3100.
44. Markman M, Kennedy A, Webster K, et al.: Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/ paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000, 78:369–372. DOI: 10.1006/gyno.2000.5921
45. Shapiro JD, Millward MJ, Rischin D, et al.: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996, 63:89–93. DOI: 10.1006/gyno.1996.0284
46. Bajetta E, Di Leo A, Biganzoli L, et al.: Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996, 14:2546–2551.
47. Burger RA, Di Saia PJ, Roberts JA, et al.: Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 1999, 72:148–153. DOI: 10.1006/gyno.1998.5243
48. Francis P, Schneider J, Hann L, et al.: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994, 12:2301–2308.
49. Piccart MJ, Gore M, ten Bokkel Huinink WW, et al.: Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995, 87:676–681. DOI: 10.1093/jnci/87.9.676
50. Verschraegen CF, Sittisomwong T, Kudelka AP, et al.: Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000, 18:2733–2739.
51. Fennelly D, Aghajanian C, Shapiro F, et al.: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997, 15:187–192.
52. Sutton GP, Blessing JM, Homesley HD, et al.: Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1989, 7:1672–1676.
53. Sorenson P, Pfeiffer P, Bertelsen K: A Phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 1995, 56:75–78. DOI: 10.1006/gyno.1995.1012
54. Markman M, Hakes T, Reichman B, et al.: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992, 10:243–248.
55. Markman M, Kennedy A, Sutton G, et al.: Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 1998, 70:272–274. DOI: 10.1006/gyno.1998.5065
56. Hatch KD, Beecham JB, Blessing JA, et al.: Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991, 68:269–271. DOI: 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O
57. Ahlgren JD, Ellison NM, Gottliev RJ, et al.: Hormonal palliation of chemoresistant ovarian cancer: three consecutive Phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993, 11:1957–1968.